CN206604008U - A kind of medicine-coated balloon dilating catheter - Google Patents
A kind of medicine-coated balloon dilating catheter Download PDFInfo
- Publication number
- CN206604008U CN206604008U CN201620976374.1U CN201620976374U CN206604008U CN 206604008 U CN206604008 U CN 206604008U CN 201620976374 U CN201620976374 U CN 201620976374U CN 206604008 U CN206604008 U CN 206604008U
- Authority
- CN
- China
- Prior art keywords
- coating
- dilating catheter
- sacculus
- medicine
- internal layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The utility model belongs to technical field of medical instruments, more particularly to a kind of medicine-coated balloon dilating catheter.Medicine-coated balloon dilating catheter includes sacculus dilating catheter body and medication coat; the medication coat is coated on the sacculus dilating catheter body surface; the medication coat exceptionally layer and internal layer, outer layer are water soluble protective layer, and internal layer is active drug and excipient；The active drug and the mass ratio of excipient are 1:The mass ratio of (0.2 2), internal layer and outer layer is 1:(0.3‑3).
Description
Technical field
The utility model belongs to technical field of medical instruments, more particularly to a kind of medicine-coated balloon dilating catheter.
Background technology
In recent years, in the treatment of hemadostewnosis, Stent is applied commonplace.Earlier studies have shown that, metal
Bare bracket (BMS) has high therapeutic effect to coronary artery hemadostewnosis, but occur by being strutted to the physical of blood vessel
The ISR of certain probability.The bracket for eluting medicament (DES) that later stage occurs has carried out antithrombotic on the basis of bare metal stent
The coating of medicine, by suppressing endometrial hyperplasia, carrys out further pre- anti-restenosis.But, it is all to be directed to hemadostewnosis or close
The PCI of plug all without the generation that diseased region ISR is completely eliminated, it is postoperative still have 10% restenosis rate.
Early in 2004, medicine-coated balloon was used for zoopery by Scheller etc. first, explores medicine-coated balloon
Convey anti-proliferative drugs and suppress the validity of endometrial hyperplasia, and two kinds of coating technologies, three kinds of medicament contgs are contrasted
Analysis experiment.Almost simultaneously, Speck etc. compares taxol drug coating balloon expandable by zoopery, in coronary artery in detail
The mixed liquor of taxol and contrast agent, implantation sirolimus drug FirebirdTM these three processing methods are directly injected into animal mould
The difference of type coronary endometrium proliferation function.Cremers in 2009 etc. compares two using hog coronary artery stenosis model
Plant the difference of different taxol drug sacculus coating technologies.First method is to mix taxol with water-soluble base Iopromide
Balloon surface is applied to after conjunction；Second method is to select shaggy sacculus, and taxol is applied directly to coarse ball
Capsule surface.Test result indicates that, second method do not show affirmative, statistically significant reduction reangiostenosis or
Mitigate the effect of neointimal thickness and neointimal area, this also illustrates that in medicine-coated balloon mesostroma be critically important.
Have been approved by listing at present or the medicine-coated balloon that will list has ten several.In the selection of active drug,
Each medicinal balloon have selected the taxol that tissue can be made quickly to absorb.And in the selection of excipient, German Bei Lang productions
Sequent Please medicament elutions sacculus, as excipient, is got the attention using Iopromide.U.S.'s Medtronic is public
It is urea to take charge of the excipient used in IN.PACT medicine-coated balloons series, and urea is human body metabolite in itself.GmbH
The Dior II of company's production is using natural shellac resins coating as drug matrices, and taxol is with matrix according to 1:Using micro- after 1 mixing
Siphon method forms smooth nano-scale coating in balloon surface, and taxol active component is 3 μ g/mm2, with hydrophilic purple
Gel coating water-swellable and become loose, taxol therein is under pressure from balloon surface quick release to vascular wall.
During design medicine coating foley's tube, the characteristic of foley's tube in itself is not only considered, it is closer
With reference to application of the drug coated balloon catheter in actual operation.At present, the maximum difficult point of medicine-coated balloon application is exactly such as
What makes the sacculus of certain medicine in load reduce loss as far as possible during conveying, and reaches target lesion portion in medicine-coated balloon
Position and after strutting, medicine discharges rapidly within certain time (30s~60s), with reach higher Drug bioavailability and
Therapeutic effect.In addition, as the excipient of important component, also to be examined in addition to morphologically to active drug disperse
Consider its biocompatibility, and develop the new advantage such as anticoagulation on this basis, Efficient Development simultaneously utilizes single substance
Multi-efficiency.
Utility model content
The utility model provides a kind of medicine-coated balloon dilating catheter, and concrete technical scheme is as follows：
A kind of medicine-coated balloon dilating catheter, including sacculus dilating catheter body and medication coat, the medication coat
It is coated on the sacculus dilating catheter body surface, the medication coat exceptionally layer and internal layer, outer layer is water soluble protective layer,
Internal layer can be protected not washed away in sacculus dilating catheter course of conveying so as to protect internal layer, and with blood coagulation resisting function；It is interior
Layer is active drug and excipient.The active drug and the mass ratio of excipient are 1:The quality of (0.2-2), internal layer and outer layer
Than for 1:(0.3-3).
The active drug be can suppress smooth muscle cell proliferation and migration medicine, including but not limited to taxol,
Paclitaxel derivatives, rapamycin, rapamycin derivative.
The excipient is citric acid, on the one hand adds the scattered of active drug, on the other hand hinders to a certain extent
Stop blood clotting, reach double effects.
The water soluble protective layer is liquaemin layer or sodium citrate layer.
The sacculus dilating catheter body uses disposable sacculus dilating catheter, and need to pass through certain sterilization process
Reused after being sterilized.
(1) a kind of the first preparation method of medicine-coated balloon dilating catheter as described above, comprises the following steps：
(1) the disposable sterile sacculus dilating catheter completed is put into spraying equipment, and it is fixed；
(2) active drug and excipient are dissolved in organic solvent, are configured to 0.5%-5% solution, treat in solution
After dissolving, solution all is shaken with ultrasonator for active drug and excipient, and by gas in solution, all concussion is discharged, with spray
Automatic doubler surface glouer carries out internal layer spraying, controls to be dried after the completion of upper dose, spraying by the way of weighing；The organic solvent
For tetrahydrofuran, methanol, ethanol；
(3) material for preparing water soluble protective layer is dissolved in water for injection, stirred in dissolving to being configured to
0.5%-50% solution, solution is shaken with ultrasonator, after gas in solution all concussion discharge, carries out outer layer painting
Cover；The mode of outer layer coating is carries out outer layer spraying with spraying equipment, or by the balloon region of medicine-coated balloon dilating catheter
Domain and front end are immersed in the solution of step (3) preparation；
(4) after the completion of the coating of double coatings, it is put into insulating box and accelerates to dry 1h-2h at 40 DEG C -80 DEG C, then carry out
Three valves are folded, and cover PTFE protective cases on the double coating areas of sacculus, are loaded in special container, are obtained described medication coat
Sacculus dilating catheter.
(2) a kind of second of preparation method of medicine-coated balloon dilating catheter as described above, comprises the following steps：
(1) the disposable sterile sacculus dilating catheter completed is put into spraying equipment, and it is fixed；
(2) active drug and excipient are dissolved in organic solvent, are configured to 0.5%-5% solution, treat in solution
After dissolving, solution all is shaken with ultrasonator for active drug and excipient, and by gas in solution, all concussion is discharged, with spray
Automatic doubler surface glouer carries out internal layer spraying, controls to be dried after the completion of upper dose, spraying by the way of weighing；The organic solvent
For tetrahydrofuran, methanol, ethanol；
(3) after the completion of the coating of internal layer coating, three valve foldings are carried out；
(4) material for preparing water soluble protective layer is dissolved in water for injection, stirred in dissolving to being configured to
0.5%-50% solution, solution is shaken with ultrasonator, after gas in solution all concussion discharge, carries out outer layer painting
Cover；The mode of outer layer coating is carries out outer layer spraying with spraying equipment, or by the balloon region of medicine-coated balloon dilating catheter
Domain and front end are immersed in the solution of step (4) preparation；
(5) after the completion of the coating of double coatings, it is put into insulating box and accelerates to dry 1h-2h at 40 DEG C -80 DEG C, then in ball
PTFE protective cases are put on the double coating areas of capsule, loads in special container, obtains described medicine-coated balloon dilating catheter.
The utility model internal layer coating uses distinctive spraying coating process, is selecting appropriate solvent, adjustment spraying equipment ginseng
Count and select under appropriate drying process, make the active drug and inborn nature agent molecule of balloon surface dispersed in particulate form,
Insoluble drug release of the sacculus in target lesion position is effectively improved, the bioavailability of active drug is improved.
The utility model outer coating uses the water soluble molecules with anticoagulant effect, passes through the side of spraying or dip-coating
Formula is assigned on the internal layer of sacculus effective coverage, and internal layer is protected to a certain extent, and liquid body does not wash away, and on the other hand slow down defeated
Blood clotting during sending, improves the ability that medicine-coated balloon dilating catheter reaches target vessel.
The principle of internal layer spraying as shown in Fig. 2 solvent molecule wrapping inner layer active drug and excipient are after nozzle ejection,
Microballoon is formed, in nozzle to balloon surface distance (D), solvent gradually volatilizees, when microballoon is sprayed onto balloon surface, solvent volatilization
More than 80%, internal layer molecule forms fine and close and uniform coating in balloon surface, and remaining solvent by volatilizing or in constant temperature naturally
Heating accelerates volatilization and removed in case.
Outer water soluble protective layer is assigned on internal layer by way of dip-coating or spraying, mode such as Fig. 2 institutes of spraying
Show, the mode of dip-coating is as shown in Figure 3.The foley's tube for being coated with internal layer coating is suppressed, makes sacculus effective coverage outer surface complete
Strut entirely, or be in sacculus effective coverage through folding in the foley's tube by internal layer coating is coated with and fold roll-up state,
Then sacculus effective coverage and front end are immersed in outer layer protection molecular solution, keep 1-20s after spontaneously dried or
Heating accelerates to dry to obtain outer water soluble protective layer in insulating box.
Medicine-releasing performance is the important performance of medicine-coated balloon dilating catheter, is led in medicine-coated balloon expansion
Guan Zhong, the insoluble drug release of internal layer and the rapid dissolving co- controlling insoluble drug release ability of outer layer, according to Fig. 2, in internal layer spray
During painting, the quick volatilization of solvent can make internal layer active drug and inborn nature agent molecule more efficiently uniform in particulate form
Spread out, in the organic solvent, volatility is tetrahydrofuran>Methanol>Ethanol, more excellent can select tetrahydrofuran to make
For internal layer solvent, but in view of the security performance of medical device product, the dissolvent residual of medicine-coated balloon dilating catheter will be made
For an important indicator, in the organic solvent, security is tetrahydrofuran<Methanol<Ethanol, so in solvent selection,
Equilibrium product characteristic is wanted, or dissolvent residual is reduced with certain means and methods.
Medicine-coated balloon dilating catheter of the present utility model, coating uniform is stable, by the parcel of outer coating, with ball
Capsule dependency is good, and the internal layer loss that active drug and excipient are loaded with medicine-coated balloon dilating catheter course of conveying is micro-
It is small, reach behind target vessel position, in 1min, most internal layer active drugs and excipient discharge, active drug quilt
Tissue resorption, excipient is dissolved among blood with microspheres form, does not result in thrombus or blood coagulation situation occurs, be greatly enhanced
Security.
Brief description of the drawings
Fig. 1 is medicine-coated balloon dilating catheter overall schematic；
Fig. 2 is medicine-coated balloon dilating catheter medication coat schematic diagram；
Fig. 3 is medicine-coated balloon dilating catheter profile；
Fig. 4 is that internal layer sprays principle schematic；
Fig. 5 is outer layer dip coating manner schematic diagram；Wherein, figure (a) makes for the foley's tube for being coated with internal layer coating is suppressed
Sacculus effective coverage outer surface is strutted completely, and figure (b) is that will be coated with the foley's tube of internal layer coating through folding, and makes sacculus effective
Region, which is in, folds roll-up state.
Embodiment
The structure of medicine-coated balloon dilating catheter as shown in Figure 1, Figure 2 and Figure 3, wherein 1 be sacculus dilating catheter point
End, 2 be sacculus, and 3 be inner tube, and 4 be medication coat, and 5 be radiopaque mark (platinum loop), and 6 be outer tube, and 7 be side opening (RX mouthfuls), 8
It is transition point for protection draw point, 9,10 be Marking ring, and 11 be hypotube, and 12 be catheter stiffener, and 13 be catheter block (needle stand/hand
Handle), 14 be specification, and 15 be outer coating, and 16 be internal layer coating.
The spraying principle of internal layer is as shown in figure 4, wherein 2 be sacculus, and 17 be solvent, and 18 be internal layer molecule.
Outer layer dip coating manner is as shown in figure 5, wherein, 19 be the foley's tube with internal layer coating, and 20 be outer layer protection point
Sub- solution, Fig. 5 (a) makes sacculus effective coverage outer surface strut completely for the foley's tube for being coated with internal layer coating is suppressed, and schemes
5 (b) is that will be coated with the foley's tube of internal layer coating through folding, and is in sacculus effective coverage and folds roll-up state.
Carry out united analysis below by way of specific experiment method and assessment indicator and evaluate involved medicine-coated balloon expansion
The performance of conduit, weighs and detects, experiment uses sacculus for the semi-manufactured fashion with sacculus, not finished product one for convenience
Secondary property uses sacculus dilating catheter.In embodiment 1-7, take five samples to carry out internal layer loss amount test respectively, take five samples
Drug release rate test is carried out, takes five samples to carry out dissolvent residual test.Embodiment 1
1st, the coating of internal layer coating：
As shown in Figure 4, the semi-finished product with sacculus completed are weighed and be put into spraying equipment after record data, and
It is fixed.
With ten a ten thousandth balance accurate weighing 0.05g taxols and 0.05g citric acids, it is put into 10ml volumetric flasks,
10ml methanol is added in volumetric flask, after after taxol all dissolving, is put on ultrasonic vibration machine and shakes 20s, make taxol
Citric acid-methanol solution.
Spraying equipment parameter is adjusted, the taxol prepared citric acid-methanol solution is uniformly sprayed on ball with spraying equipment
Weigh weight and record data on capsule, after the completion of spraying in the balance.
2nd, the coating of outer coating：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.05g liquaemins, it is put into 10ml volumetric flasks, in capacity
10ml waters for injection are added in bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin water
Solution.
The semi-finished product with sacculus for having coated internal layer coating are fixed on spraying equipment, and it is fixed, and adjustment spraying is set
The heparin sodium water solution prepared, is uniformly sprayed on sacculus by standby parameter with spraying equipment.Weigh weight after 60 DEG C of dryings in the balance simultaneously
Record data.
Sacculus carries out three valve foldings, covers PTFE protective cases, packs and sterilize, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test：
The PBS that 10ml pH value is 7.4 will be filled to be put into constant temperature oscillator, the sacculus of inside and outside bilayer will be scribbled
PTFE protective cases are removed, and are hung into buffer solution, and it is taking-up after 80rpm, 15s to set concussion frequency, dries, weighs, and calculates internal layer
Loss amount.
The PBS that 10ml pH value is 7.4 will be filled to be put into constant temperature oscillator, the ball of internal layer coating will be merely coated with
Capsule PTFE protective cases are removed and are opened sacculus completely with 6atm, hang into buffer solution, and it is 100rpm, 1min to set concussion frequency
After take out, dry, weigh, calculate drug release rate.
4th, medicine-coated balloon dilating catheter dissolvent residual is tested：
The sacculus PTFE protective cases for scribbling inside and outside bilayer are removed, gas chromatographic analysis methanol content is used.
Embodiment 2
1st, the coating of internal layer coating：
As shown in Figure 4, the semi-finished product with sacculus completed are weighed and record data and be put into spraying equipment, and
It is fixed.
With ten a ten thousandth balance accurate weighing 0.05g taxols and 0.1g citric acids, it is put into 10ml volumetric flasks, is holding
10ml methanol is added in measuring bottle, after after taxol all dissolving, is put on ultrasonic vibration machine and shakes 20s, make taxol Chinese holly
Rafter acid-methanol solution.
Spraying equipment parameter is adjusted, the taxol prepared citric acid-methanol solution is uniformly sprayed on ball with spraying equipment
Weigh weight and record data on capsule, after the completion of spraying in the balance.
2nd, the coating of outer coating is identical with example 1.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
Embodiment 3
1st, the coating of internal layer coating：
As shown in Figure 4, the semi-finished product with sacculus completed are weighed and record data and be put into spraying equipment, and
It is fixed.
With ten a ten thousandth balance accurate weighing 0.05g taxols and 0.05g citric acids, it is put into 10ml volumetric flasks,
10ml methanol is added in volumetric flask, after after taxol all dissolving, is put on ultrasonic vibration machine and shakes 20s, make taxol
Citric acid-methanol solution.
Spraying equipment parameter is adjusted, the taxol prepared citric acid-methanol solution is uniformly sprayed on ball with spraying equipment
Weigh weight and record data on capsule, after the completion of spraying in the balance.
2nd, the coating of outer coating：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.1g liquaemins, it is put into 10ml volumetric flasks, in capacity
10ml waters for injection are added in bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin water
Solution.
The semi-finished product with sacculus for having coated internal layer coating are fixed on spraying equipment, and it is fixed, and adjustment spraying is set
The heparin sodium water solution prepared, is uniformly sprayed on sacculus by standby parameter with spraying equipment.Weigh weight after 60 DEG C of dryings in the balance simultaneously
Record data.
Sacculus carries out three valve foldings, covers PTFE protective cases, packs and sterilize, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
Embodiment 4
1st, the coating of internal layer coating：
The coating of internal layer coating is identical with example 1.
2nd, the coating of outer coating：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.1g sodium citrates, it is put into 10ml volumetric flasks, is holding
10ml waters for injection are added in measuring bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin
The aqueous solution.
The semi-finished product with sacculus for having coated internal layer coating are fixed on spraying equipment, and it is fixed, and adjustment spraying is set
The heparin sodium water solution prepared, is uniformly sprayed on sacculus by standby parameter with spraying equipment.Weigh weight after 60 DEG C of dryings in the balance simultaneously
Record data.
Sacculus carries out three valve foldings, covers PTFE protective cases, packs and sterilize, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
Embodiment 5
1st, the coating of internal layer coating：
As shown in Figure 4, the semi-finished product with sacculus completed are weighed and record data and be put into spraying equipment, and
It is fixed.
With ten a ten thousandth balance accurate weighing 0.05g taxols and 0.05g citric acids, it is put into 10ml volumetric flasks,
10ml tetrahydrofurans are added in volumetric flask, after after taxol all dissolving, is put on ultrasonic vibration machine and shakes 20s, make purple
China fir alcohol citric acid-tetrahydrofuran solution.
Spraying equipment parameter is adjusted, is uniformly sprayed the taxol prepared citric acid-tetrahydrofuran solution with spraying equipment
Weighed and record data in being weighed in the balance on sacculus, after the completion of spraying.
2nd, the coating of outer coating：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.05g sodium citrates, it is put into 10ml volumetric flasks, is holding
10ml waters for injection are added in measuring bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin
The aqueous solution.
The semi-finished product with sacculus for having coated internal layer coating are fixed on spraying equipment, and it is fixed, and adjustment spraying is set
The heparin sodium water solution prepared, is uniformly sprayed on sacculus by standby parameter with spraying equipment.Weigh weight after 60 DEG C of dryings in the balance simultaneously
Record data.
Sacculus carries out three valve foldings, covers PTFE protective cases, packs and sterilize, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
Embodiment 6
1st, the coating of internal layer coating：
The coating of internal layer coating is same as Example 5.
2nd, the coating of outer layer figure layer：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.05g liquaemins, it is put into 10ml volumetric flasks, in capacity
10ml waters for injection are added in bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin water
Solution.
The semi-finished product with sacculus for having coated internal layer coating are subjected to three valve foldings, spraying equipment is fixed on after folding
On, and it is fixed, spraying equipment parameter is adjusted, is uniformly sprayed on the heparin sodium water solution prepared on sacculus with spraying equipment.60
DEG C dry after weigh in the balance weight and record data.
Sacculus covers PTFE protective cases, packs and sterilizes, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
Embodiment 7
1st, the coating of internal layer coating：
The coating of internal layer coating is same as Example 5.
2nd, the coating of outer coating：
As shown in Figure 5, with ten a ten thousandth balance accurate weighing 0.05g liquaemins, it is put into 10ml volumetric flasks, in capacity
10ml waters for injection are added in bottle, 20s is shaken after being put into after liquaemin all dissolving on ultrasonic vibration machine, makes liquaemin water
Solution.
The semi-finished product with sacculus for having coated internal layer coating are subjected to three valve foldings, is hung on after folding and fills liquaemin water
Dip-coating is carried out in the beaker of solution.Weigh weight and record data after 60 DEG C of dryings in the balance.
Sacculus covers PTFE protective cases, packs and sterilizes, to be tested.
3rd, drug delivery process internal layer loss amount and drug release rate test are identical with example 1.
4th, the test of medicine-coated balloon dilating catheter dissolvent residual is identical with example 1.
The data result that above example is drawn is as shown in table 1.
Above is referred to seven kinds formula and experimental data only obtained by laboratory, it can be seen that use figuration not of the same race
The experimental result obtained under agent, non-same amount excipient, different solvents, different outer substances, different outer layer coating methods is that have difference
Different, from the point of view of insoluble drug release effect, the scheme of embodiment 2 is optimal selection.Remaining scheme can also be adjusted according to actual conditions
Some data obtain optimum results.
Claims (1)
1. a kind of medicine-coated balloon dilating catheter, including sacculus dilating catheter body and medication coat, the medication coat bag
It is overlying on the sacculus dilating catheter body surface, it is characterised in that the medication coat exceptionally layer and internal layer, outer layer is water-soluble
Property protective layer, the water soluble protective layer is liquaemin layer or sodium citrate layer, and the sacculus dilating catheter body is using once
Property use sterile sacculus dilating catheter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620976374.1U CN206604008U (en) | 2016-08-29 | 2016-08-29 | A kind of medicine-coated balloon dilating catheter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620976374.1U CN206604008U (en) | 2016-08-29 | 2016-08-29 | A kind of medicine-coated balloon dilating catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206604008U true CN206604008U (en) | 2017-11-03 |
Family
ID=60172499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620976374.1U Active CN206604008U (en) | 2016-08-29 | 2016-08-29 | A kind of medicine-coated balloon dilating catheter |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206604008U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481826A (en) * | 2018-11-05 | 2019-03-19 | 南京友德邦医疗科技有限公司 | A kind of drug coated balloon catheter and preparation method thereof |
| CN109985280A (en) * | 2017-12-29 | 2019-07-09 | 先健科技(深圳)有限公司 | Medicinal balloon and preparation method thereof |
| CN112704802A (en) * | 2019-10-25 | 2021-04-27 | 河南驼人医疗器械集团有限公司 | Balloon dilatation catheter and preparation method thereof |
| CN114832214A (en) * | 2022-04-25 | 2022-08-02 | 上海畅德医疗科技有限公司 | Medicinal balloon catheter and preparation method and application thereof |
-
2016
- 2016-08-29 CN CN201620976374.1U patent/CN206604008U/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109985280A (en) * | 2017-12-29 | 2019-07-09 | 先健科技(深圳)有限公司 | Medicinal balloon and preparation method thereof |
| CN109481826A (en) * | 2018-11-05 | 2019-03-19 | 南京友德邦医疗科技有限公司 | A kind of drug coated balloon catheter and preparation method thereof |
| CN112704802A (en) * | 2019-10-25 | 2021-04-27 | 河南驼人医疗器械集团有限公司 | Balloon dilatation catheter and preparation method thereof |
| CN114832214A (en) * | 2022-04-25 | 2022-08-02 | 上海畅德医疗科技有限公司 | Medicinal balloon catheter and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106237485A (en) | A kind of medicine-coated balloon dilating catheter and preparation method thereof | |
| CN206604008U (en) | A kind of medicine-coated balloon dilating catheter | |
| CN106237395B (en) | A kind of medicine-coated balloon and preparation method thereof | |
| CN106620887B (en) | A kind of production method of medicinal balloon | |
| EP1986610B1 (en) | Loading of hydrophobic drugs into hydrophilic polymer delivery systems | |
| CN104231193B (en) | A kind of layer crosslinking nano grain of pH and redox sensitive and its preparation method and application | |
| CN110292701A (en) | A kind of medicine eluting balloon catheter and preparation method thereof | |
| Anderson et al. | Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drug-coated balloons | |
| CN110496251A (en) | Cation nanometer drug and preparation method thereof carries medicine implanted medical device | |
| CN106334220B (en) | The coating processes of medication coat on medical instrument | |
| CN103566415B (en) | A kind of human vas implant of coated on both sides and preparation method thereof | |
| CN109985280A (en) | Medicinal balloon and preparation method thereof | |
| US10064981B2 (en) | Catheter with drug coating | |
| CN106178233A (en) | The preparation method of medicine balloon dilating catheter and flap winding sacculus | |
| CN104922735A (en) | Method for manufacturing medicine balloons | |
| US11013832B2 (en) | Formulations for tailored drug release | |
| CN106267377A (en) | Drug coated balloon catheter | |
| CN104984412A (en) | Preparation method for paclitaxel coating on surface of drug balloon | |
| CN114259606A (en) | Drug balloon catheter and surface treatment method of drug balloon | |
| CN107496998B (en) | Peripheral drug eluting stent and preparation and application thereof | |
| CN110251738A (en) | The preparation method and medicinal balloon of medicinal balloon | |
| CN204840617U (en) | Novel medicine elution sacculus pipe | |
| CN107921002A (en) | The chitosan of hydroxypropyl methylcellulose grafting and its method for sustained drug delivery | |
| CN107754022A (en) | A kind of medication coat and preparation method thereof | |
| CN111588914A (en) | Medicine coating for interventional or implanted medical apparatus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |